Yahoo
    Buenos Aires - Delayed Quote ARS

    Merck & Co., Inc. (MRK.BA)

    49,600.00 +1,420.00 (+2.95%)
    At close: October 30 at 4:59:04 PM GMT-3
    Loading Chart for MRK.BA
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Merck stock rises as its cancer strategy gets personal

    Merck stock rises as its cancer strategy gets personal
    TheStreet 19h ago
    MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds

    MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
    StockStory 1d ago
    How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine Data

    How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine Data
    Simply Wall St. 2d ago
    Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze

    Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze
    Simply Wall St. 2d ago
    Why Merck Stock Flew Higher on Friday

    Why Merck Stock Flew Higher on Friday
    Motley Fool 2d ago
    Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs

    Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs
    24/7 Wall St. 2d ago
    CMMB Celebrates New Distribution Center at the Brethren Service Center with Ribbon-Cutting Ceremony

    CMMB Celebrates New Distribution Center at the Brethren Service Center with Ribbon-Cutting Ceremony
    GlobeNewswire 2d ago
    This week in charts: ESMO’s winners and losers

    This week in charts: ESMO’s winners and losers
    BioPharma Dive 2d ago
    EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales

    EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales
    Zacks 2d ago
    $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends

    $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
    24/7 Wall St. 2d ago
    Global CRISPR Fluorescence Assays Market Report 2026 | Capitalize on 19.5% CAGR to 2030 with Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences Driving Multiplex Diagnostics

    Global CRISPR Fluorescence Assays Market Report 2026 | Capitalize on 19.5% CAGR to 2030 with Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences Driving Multiplex Diagnostics
    GlobeNewswire 2d ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: